{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:47:30Z","timestamp":1792154850034,"version":"4.4.0"},"reference-count":68,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Poor manufacturing quality in healthcare and cosmetic products expose people to danger and needs further categorization and assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study reviewed Food and Drug Administration (FDA) records to identify major types of quality issues, the type of products involved, and patterns occurring over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The \u201cFDA Health Fraud Product\u201d and \u201cFDA Recalls, Market Withdrawals, and Safety Alerts\u201d databases were assessed from June 4, 2010, through May 30, 2026. Drugs, cosmetics, and dietary supplements\/quasi-legal products with verified manufacturing quality issues were included. Products were sorted by product type and FDA warning letters or official reports were reviewed and categorized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 266 reviewed entries, 195 manufacturing quality issues were elucidated from 184 unique products. Drugs accounted for 70% of issues, cosmetics for 21%, and dietary supplement\/quasi-legal products for 9%, respectively. Overall, chemical contamination (30%), procedural or testing issues (29%), and microbial contamination (19%) comprised 78% of identified issues. Drug issues were primarily procedural\/testing, chemical contamination, and microbial contamination; cosmetic issues were predominantly elemental impurities and chemical contamination; and dietary supplement\/quasi-legal issues were mainly microbial contamination, procedural\/testing, and elemental impurities. Particulate contamination occurred only in drugs. The number of issues per year showed no consistent trend, but spiked in 2020, 2022, 2024, and 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>Manufacturing quality problems varied substantially by product category and occurred in irregular clusters. Inconsistent FDA reporting practices and fluctuations in agency surveillance may have contributed to these patterns. Budgetary cuts to the FDA could increase consumer exposure to manufacturing issues.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280261492707","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:24:43Z","timestamp":1791959083000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Manufacturing Quality Issues in Healthcare and Cosmetics: An Analysis of FDA Surveillance Data"],"prefix":"10.1177","author":[{"given":"Ethan M.","family":"Coleman","sequence":"first","affiliation":[{"name":"School of Pharmacy and Pharmaceutical Sciences, University of Connecticut, Storrs, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9367-4893","authenticated-orcid":false,"given":"C. Michael","family":"White","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Center for Addiction Science and Innovation, School of Pharmacy and Pharmaceutical Sciences, University of Connecticut, Storrs, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026739"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068233"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","unstructured":"Yip L Bixler D Brooks DE et al. Serious adverse health events including death associated with ingesting alcohol-based hand sanitizers containing methanol\u2014Arizona and New Mexico May\u2013June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1070-1073. Accessed August 12 2026. https:\/\/www.cdc.gov\/mmwr\/volumes\/69\/wr\/mm6932e1.htm","DOI":"10.15585\/mmwr.mm6932e1"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241233255"},{"key":"e_1_3_4_6_2","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research. Report on the state of pharmaceutical quality FY2025. Accessed August 12 2026. https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/report-state-pharmaceutical-quality?utm_medium=email&utm_source=govdelivery"},{"key":"e_1_3_4_7_2","unstructured":"Office of Dietary Supplements. Dietary Supplement Health and Education Act of 1994 Pub L No. 103-417. National Institutes of Health. Accessed August 12 2026. https:\/\/ods.od.nih.gov\/About\/DSHEA_Wording.aspx"},{"key":"e_1_3_4_8_2","unstructured":"Modernization of Cosmetics Regulation Act of 2022 Pub L No. 117-328 div FF title III subtitle E. Accessed August 12 2026. https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-117publ328\/pdf\/PLAW-117publ328.pdf"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251343626"},{"key":"e_1_3_4_10_2","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research. Report on the state of pharmaceutical quality: FY2019. Accessed August 12 2026. https:\/\/www.fda.gov\/media\/135046\/download"},{"key":"e_1_3_4_11_2","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research. Report on the state of pharmaceutical quality: FY2020. Accessed August 12 2026. https:\/\/www.fda.gov\/media\/151561\/download"},{"key":"e_1_3_4_12_2","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research. Report on the state of pharmaceutical quality: FY2021. Accessed August 12 2026. https:\/\/www.fda.gov\/media\/161172\/download"},{"key":"e_1_3_4_13_2","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research. Report on the state of pharmaceutical quality: FY2023. Accessed August 12 2026. https:\/\/www.fda.gov\/media\/179254\/download"},{"key":"e_1_3_4_14_2","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research. Report on the state of pharmaceutical quality: FY2024. Accessed August 12 2026. https:\/\/www.fda.gov\/media\/188236\/download"},{"key":"e_1_3_4_15_2","unstructured":"U.S. Government Accountability Office. Drug Safety: FDA should implement strategies to retain its inspection workforce. GAO-25-106775. Accessed August 12 2026. https:\/\/www.gao.gov\/products\/gao-25-106775"},{"key":"e_1_3_4_16_2","unstructured":"Long J. FDA still finding same cGMP deficiencies at dietary supplement facilities. SupplySide Supplement Journal. November 1 2018. Accessed August 12 2026. https:\/\/www.supplysidesj.com\/supplement-regulations\/fda-still-finding-same-cgmp-deficiencies-at-dietary-supplement-facilities"},{"key":"e_1_3_4_17_2","unstructured":"Long J. FDA inspections of dietary supplement facilities fall\u2014again. SupplySide Supplement Journal. December 13 2021. Accessed August 12 2026. https:\/\/www.supplysidesj.com\/supplement-regulations\/fda-inspections-of-dietary-supplement-facilities-fall-again"},{"key":"e_1_3_4_18_2","unstructured":"Long J. FDA more than doubles annual foreign inspections of dietary supplements. SupplySide Supplement Journal. December 19 2023. Accessed August 12 2026. https:\/\/www.supplysidesj.com\/supplement-regulations\/fda-doubles-foreign-inspections-of-dietary-supplements-"},{"key":"e_1_3_4_19_2","unstructured":"Long J. Top FDA cGMP citation in FY23 tied to product specifications. SupplySide Supplement Journal. January 8 2024. Accessed August 12 2026. https:\/\/www.supplysidesj.com\/supplement-regulations\/top-fda-cgmp-citation-in-fy23-tied-to-product-specifications"},{"key":"e_1_3_4_20_2","unstructured":"Long J. FDA increases annual domestic foreign dietary supplement inspections. SupplySide Supplement Journal. December 13 2024. Accessed August 12 2026. https:\/\/www.supplysidesj.com\/supplement-regulations\/fda-increases-annual-domestic-foreign-dietary-supplement-inspections"},{"key":"e_1_3_4_21_2","unstructured":"Pavlick L. FDA in 2025: navigating changes in food and dietary supplement investigations. SupplySide Supplement Journal. April 17 2025. Accessed August 12 2026. https:\/\/www.supplysidesj.com\/supplement-regulations\/fda-in-2025-navigating-changes-in-food-and-dietary-supplement-investigations"},{"key":"e_1_3_4_22_2","unstructured":"U.S. House Committee on Energy and Commerce. Pallone requests updated information on FDA\u2019s inspections of imported cosmetics 2019. Accessed August 12 2026. https:\/\/democrats-energycommerce.house.gov\/newsroom\/press-releases\/pallone-requests-updated-information-on-fda-s-inspections-of-imported"},{"key":"e_1_3_4_23_2","unstructured":"Congressional Research Service. FDA regulation of cosmetics and personal care products under the modernization of cosmetics regulation Act of 2022 (MoCRA). Report R47826. Accessed August 12 2026. https:\/\/www.congress.gov\/crs_external_products\/R\/PDF\/R47826\/R47826.1.pdf"},{"key":"e_1_3_4_24_2","unstructured":"Foley & Lardner LLP. How MoCRA is reshaping FDA oversight of cosmetics in 2026. March 12 2026. Accessed August 12 2026. https:\/\/www.foley.com\/insights\/publications\/2026\/03\/how-mocra-is-reshaping-fda-oversight-of-cosmetics-in-2026\/"},{"key":"e_1_3_4_25_2","unstructured":"U.S. Food and Drug Administration. Modernization of cosmetics regulation Act of 2022 (MoCRA). March 13 2026. Accessed August 12 2026. https:\/\/www.fda.gov\/cosmetics\/cosmetics-laws-regulations\/modernization-cosmetics-regulation-act-2022-mocra"},{"key":"e_1_3_4_26_2","unstructured":"U.S. Food and Drug Administration. Drug quality sampling and testing programs. Accessed August 12 2026. https:\/\/www.fda.gov\/drugs\/science-and-research-drugs\/drug-quality-sampling-and-testing-programs"},{"key":"e_1_3_4_27_2","unstructured":"U.S. Food and Drug Administration. Compliance program 7329.001: cosmetics program import and domestic. Accessed August 12 2026. https:\/\/www.fda.gov\/media\/78441\/download"},{"key":"e_1_3_4_28_2","unstructured":"U.S. Food and Drug Administration. FDA releases data from the agency\u2019s 2023 testing of talc-containing cosmetic products for asbestos. Accessed August 12 2026. https:\/\/www.fda.gov\/cosmetics\/cosmetics-news-events\/fda-releases-data-agencys-2023-testing-talc-containing-cosmetic-products-asbestos"},{"key":"e_1_3_4_29_2","unstructured":"U.S. Food and Drug Administration. FDA\u2019s testing of cosmetics for arsenic cadmium chromium cobalt lead mercury and nickel content. Accessed August 12 2026. https:\/\/www.fda.gov\/cosmetics\/potential-contaminants-cosmetics\/fdas-testing-cosmetics-arsenic-cadmium-chromium-cobalt-lead-mercury-and-nickel-content"},{"key":"e_1_3_4_30_2","unstructured":"U.S. House Committee on Energy and Commerce. Pallone releases letter from FDA outlining troubling statistics on imported cosmetic products. August 2 2017. Accessed August 12 2026. https:\/\/democrats-energycommerce.house.gov\/newsroom\/press-releases\/pallone-releases-letter-from-fda-outlining-troubling-statistics-on-imported"},{"key":"e_1_3_4_31_2","unstructured":"Definitions Federal Food Drug and Cosmetic Act 21 USC \u00a7321. Accessed August 12 2026. https:\/\/www.law.cornell.edu\/uscode\/text\/21\/321"},{"key":"e_1_3_4_32_2","unstructured":"U.S. Food and Drug Administration. Is it a cosmetic a drug or both? (Or is it soap?). Accessed August 12 2026. https:\/\/www.fda.gov\/cosmetics\/cosmetics-laws-regulations\/it-cosmetic-drug-or-both-or-it-soap"},{"key":"e_1_3_4_33_2","unstructured":"World Health Organization. Mercury in skin lightening products. World Health Organization; 2019. Accessed August 6 2026. https:\/\/iris.who.int\/handle\/10665\/329480"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00081"},{"key":"e_1_3_4_35_2","unstructured":"U.S. Environmental Protection Agency. Health effects of exposures to mercury. Accessed August 12 2026. https:\/\/19january2021snapshot.epa.gov\/mercury\/health-effects-exposures-mercury_.html"},{"key":"e_1_3_4_36_2","unstructured":"U.S. Food and Drug Administration. Mercury poisoning linked to skin products. Accessed August 12 2026. https:\/\/www.fda.gov\/consumers\/consumer-updates\/mercury-poisoning-linked-skin-products"},{"key":"e_1_3_4_37_2","unstructured":"U.S. Food and Drug Administration. FDA warns consumers about skin products containing mercury and\/or hydroquinone. Accessed August 12 2026. https:\/\/www.fda.gov\/consumers\/health-fraud-scams\/fda-warns-consumers-skin-products-containing-mercury-andor-hydroquinone"},{"key":"e_1_3_4_38_2","unstructured":"New York City Department of Health and Mental Hygiene. Mercury in soaps and creams. Accessed August 12 2026. https:\/\/www.nyc.gov\/site\/doh\/health\/health-topics\/mercury-in-soaps-and-creams.page"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2024.2395552"},{"key":"e_1_3_4_40_2","unstructured":"U.S. Food and Drug Administration. Policy for testing of alcohol (ethanol) and isopropyl alcohol for methanol including during the public health emergency (COVID-19): guidance for industry. Accessed August 12 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/policy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol"},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","unstructured":"Konkel K Burkhart K Cheng C et al. Methanol poisonings from contaminated hand sanitizers identified by the United States Food and Drug Administration. Clin Toxicol. 2023;61(12):1065-1067. https:\/\/doi.org\/10.1080\/15563650.2023.2288809","DOI":"10.1080\/15563650.2023.2288809"},{"key":"e_1_3_4_42_2","unstructured":"U.S. Food and Drug Administration. Control of nitrosamine impurities in human drugs: guidance for industry. Accessed August 12 2026. https:\/\/www.fda.gov\/media\/141720\/download"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019892222"},{"key":"e_1_3_4_44_2","unstructured":"U.S. Food and Drug Administration. FDA issues warning about certain products containing toxic yellow oleander. Accessed August 12 2026. https:\/\/www.fda.gov\/food\/alerts-advisories-safety-information\/fda-issues-warning-about-certain-supplements-substituted-toxic-yellow-oleander"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7237a3"},{"key":"e_1_3_4_46_2","unstructured":"U.S. Food and Drug Administration. FDA expands warning to consumers about toxic yellow oleander purported to be nuez de la India in certain botanical weight loss products. Accessed August 12 2026. https:\/\/www.fda.gov\/food\/alerts-advisories-safety-information\/fda-expands-warning-consumers-about-toxic-yellow-oleander-purported-be-nuez-de-la-india-certain"},{"key":"e_1_3_4_47_2","unstructured":"U.S. Food and Drug Administration. Cosmetic products containing methylene chloride. Accessed August 12 2026. https:\/\/www.fda.gov\/consumers\/health-fraud-scams\/cosmetic-products-containing-methylene-chloride"},{"key":"e_1_3_4_48_2","unstructured":"National Archives. Use of methylene chloride as an ingredient of cosmetic products 21 CFR \u00a7700.19. Accessed August 12 2026. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-G\/part-700\/subpart-B\/section-700.19"},{"key":"e_1_3_4_49_2","unstructured":"U.S. Food and Drug Administration. FY 2024 FDA budget summary. Accessed August 12 2026. https:\/\/www.fda.gov\/media\/166050\/download"},{"key":"e_1_3_4_50_2","unstructured":"U.S. Food and Drug Administration. Implementation of the generic drug user fee amendments of 2012 (GDUFA). Congressional testimony. Accessed August 12 2026. https:\/\/www.fda.gov\/news-events\/congressional-testimony\/implementation-generic-drug-user-fee-amendments-2012-gdufa"},{"key":"e_1_3_4_51_2","unstructured":"U.S. Government Accountability Office. Drug Safety: FDA has conducted more foreign inspections and begun to improve its information on foreign establishments but more progress is needed. GAO-10-961. 2010. Accessed August 12 2026. https:\/\/www.gao.gov\/assets\/a310548.html"},{"key":"e_1_3_4_52_2","unstructured":"U.S. Food and Drug Administration. Registration of food facilities and other submissions. Accessed August 12 2026. https:\/\/www.fda.gov\/food\/guidance-regulation-food-and-dietary-supplements\/registration-food-facilities-and-other-submissions"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2046"},{"key":"e_1_3_4_54_2","unstructured":"U.S. Food and Drug Administration. New dietary ingredients in dietary supplements\u2014background for industry. Accessed August 12 2026. https:\/\/www.fda.gov\/food\/dietary-supplements-guidance-documents-regulatory-information\/new-dietary-ingredients-dietary-supplements-background-industry"},{"key":"e_1_3_4_55_2","unstructured":"Long J. FDA proposes DSHEA modernization in budget proposal to Biden administration. SupplySide Supplement Journal. March 9 2023. Accessed August 12 2026. https:\/\/www.supplysidesj.com\/supplement-regulations\/fda-proposes-dshea-modernization-in-budget-proposal-to-biden-administration"},{"key":"e_1_3_4_56_2","unstructured":"Sherman A. Sen. Durbin reintroduces Dietary Supplement Listing Act again. NutraIngredients. January 15 2026. Accessed August 12 2026. https:\/\/www.nutraingredients.com\/Article\/2026\/01\/15\/sen-durbin-introduces-dietary-supplement-listing-act-of-2026\/"},{"key":"e_1_3_4_57_2","unstructured":"Dietary Supplement and Nonprescription Drug Consumer Protection Act Pub L No. 109-462 120 Stat 3469 (2006). Accessed August 12 2026. https:\/\/www.govinfo.gov\/app\/details\/PLAW-109publ462"},{"key":"e_1_3_4_58_2","unstructured":"U.S. Food and Drug Administration. Response to Rep. Frank Pallone Jr. regarding imported cosmetic products. Released by the US House Committee on Energy and Commerce; August 2 2017. Accessed August 12 2026. https:\/\/www.ewg.org\/sites\/default\/files\/u352\/FDA%20Response%20to%20Rep.%20Pallone%20on%20Cosmetic%20Imports.pdf"},{"key":"e_1_3_4_59_2","unstructured":"Harris G. FDA has 6 inspectors for 3 million shipments of cosmetics. New York Times. August 2 2017. https:\/\/www.nytimes.com\/2017\/08\/02\/us\/politics\/fda-has-6-inspectors-for-3-million-shipments-of-cosmetics.html"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu17233754"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7174.2012.00212.x"},{"key":"e_1_3_4_62_2","unstructured":"U.S. Senate Special Committee on Aging. Letter to Martin A. Makary MD Commissioner of Food and Drugs regarding foreign drug quality. April 1 2025. Accessed August 12 2026. https:\/\/www.aging.senate.gov\/imo\/media\/doc\/250401_fda_on_foreign_drug_quality.pdf"},{"key":"e_1_3_4_63_2","unstructured":"U.S. Government Accountability Office. Dietary supplements: FDA may have opportunities to expand its use of reported health problems to oversee products. GAO-13-244. 2013. Accessed August 12 2026. https:\/\/www.gao.gov\/assets\/gao-13-244.pdf"},{"key":"e_1_3_4_64_2","unstructured":"U.S. Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting program. Accessed August 12 2026. https:\/\/www.fda.gov\/safety\/medwatch-fda-safety-information-and-adverse-event-reporting-program"},{"key":"e_1_3_4_65_2","unstructured":"Krietsch Boerner L. NDMA a contaminant found in multiple drugs has industry seeking sources and solutions. Chem Eng News. 2020;98(15). Accessed August 12 2026. https:\/\/cen.acs.org\/pharmaceuticals\/pharmaceutical-chemicals\/NDMA-contaminant-found-multiple-drugs\/98\/i15"},{"key":"e_1_3_4_66_2","unstructured":"U.S. Department of Health and Human Services. Fact sheet: HHS\u2019 transformation to make America healthy again. March 27 2025. Accessed August 12 2026. https:\/\/www.hhs.gov\/press-room\/hhs-restructuring-doge-fact-sheet.html"},{"key":"e_1_3_4_67_2","unstructured":"Anon. FDA Inspections in 2026: DOGE didn\u2019t cut inspectors\u2014it cut everything around them. Policy Canary. Accessed August 12 2026. https:\/\/policycanary.io\/blog\/what-doge-means-for-fda-inspections"},{"key":"#cr-split#-e_1_3_4_68_2.1","unstructured":"U.S. Food and Drug Administration. FY 2026 President's budget summary. U.S. Department of Health and Human Services"},{"key":"#cr-split#-e_1_3_4_68_2.2","unstructured":"2025. Accessed August 12 2026. https:\/\/www.fda.gov\/media\/186731\/download"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261492707","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261492707","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261492707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:55:03Z","timestamp":1792151703000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261492707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":68,"alternative-id":["10.1177\/10600280261492707"],"URL":"https:\/\/doi.org\/10.1177\/10600280261492707","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"article-number":"10600280261492707"}}